The TR Patent Scorecard 2001
Page 3 of 8
 |
|
|
|
|
| ||||||
| Company |
|
|
|
|
|
|
|  |  |
| |
| GlaxoSmithKline | 269/1 | 150/9 | 374 | 208 | 0.72 | 0.72 | 6.31 | 6.60 | 8.4 | 8.6 | |
| Pharmacia | 178/2 | 222/3 | 349 | 332 | 0.51 | 0.67 | 16.64 | 10.10 | 10.4 | 9.6 | |
| Isis Pharmaceuticals | 175/3 | 61/16 | 115 | 40 | 1.52 | 1.54 | 27.02 | 36.74 | 5.9 | 6.7 | |
| Merck | 170/4 | 190/4 | 265 | 226 | 0.64 | 0.84 | 10.23 | 9.84 | 6.5 | 6.4 | |
| Pfizer | 168/5 | 157/7 | 259 | 199 | 0.65 | 0.79 | 5.76 | 5.81 | 9.4 | 9.3 | |
| Aventis | 154/6 | 345/1 | 375 | 733 | 0.41 | 0.47 | 7.34 | 3.85 | 10.2 | 9.8 | |
| Schering | 147/7 | 68/15 | 112 | 78 | 1.31 | 0.87 | 6.10 | 5.52 | 8.2 | 8.7 | |
| Roche | 139/8 | 223/2 | 263 | 282 | 0.53 | 0.79 | 17.60 | 16.12 | 8.6 | 8.5 | |
| Eli Lilly | 125/9 | 168/6 | 174 | 205 | 0.72 | 0.82 | 7.51 | 9.43 | 8.5 | 8.7 | |
| AstraZeneca | 94/10 | 105/12 | 204 | 170 | 0.46 | 0.62 | 7.11 | 5.52 | 9.4 | 8.5 | |
| Novartis | 93/11 | 180/5 | 186 | 310 | 0.50 | 0.58 | 11.45 | 6.01 | 8.8 | 9.6 | |
| Abbott Laboratories | 88/12 | 155/8 | 133 | 166 | 0.66 | 0.93 | 6.83 | 5.01 | 9.2 | 9.4 | |
| Novo Nordisk | 75/13 | 84/13 | 183 | 132 | 0.41 | 0.64 | 3.92 | 6.79 | 7.8 | 8.2 | |
| Affymetrix | 70/14 | 13/23 | 27 | 7 | 2.60 | 1.94 | 17.15 | 12.06 | 8.1 | 6.6 | |
| Bristol-Myers Squibb | 63/15 | 123/11 | 117 | 160 | 0.54 | 0.77 | 10.38 | 9.25 | 9.8 | 8.6 | |
| BioNumerik Pharmaceuticals | 53/16 | 5/24 | 23 | 5 | 2.32 | 0.99 | 23.70 | 18.23 | 3.0 | 9.3 | |
| Alliance Pharmaceutical | 52/17 | 50/20 | 15 | 18 | 3.44 | 2.83 | 10.67 | 11.51 | 8.2 | 6.9 | |
| General Hospital | 48/18 | 52/19 | 64 | 54 | 0.75 | 0.96 | 30.09 | 35.88 | 7.3 | 8.2 | |
| Takeda Chemical | 43/19 | 57/17 | 86 | 97 | 0.50 | 0.59 | 11.47 | 3.23 | 8.2 | 9.1 | |
| Xoma | 42/20 | 27/22 | 16 | 14 | 2.61 | 1.88 | 28.75 | 45.11 | 5.3 | 5.5 | |
| American Home Products | 41/21 | 136/10 | 98 | 115 | 0.42 | 1.18 | 13.58 | 9.84 | 8.1 | 7.0 | |
| Schering-Plough | 40/22 | 54/18 | 63 | 78 | 0.64 | 0.69 | 15.70 | 10.28 | 7.0 | 10.0 | |
| Incyte Genomics | 37/23 | 71/14 | 149 | 77 | 0.25 | 0.92 | 9.42 | 10.29 | 3.9 | 4.9 | |
| Alza | 37/23 | 42/21 | 41 | 40 | 0.90 | 1.06 | 4.44 | 2.95 | 10.3 | 10.8 | |
*average
Indexing Innovation
Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics:
Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below).
Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions.
Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on.
Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors.
Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents.
0 comments. Share your thoughts » 0 comments about this story. Start the discussion »